Source: Annual Congress 2007 - New drugs for COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Joos, V. Schelfhout, F. Kanniess, A. Ludwig-Sengpiel, E. Garcia Gil, E. Massana Montejo (Ghent, Belgium; Grosshansdorf, Germany; Barcelona, Spain). Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study. Eur Respir J 2007; 30: Suppl. 51, 1299

Member's Comments

No comment yet.

Related content which might interest you: Bronchodilator/bronchoprotective effects of aclidinium bromide, a novel long-acting anticholinergic: a phase I study Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007 Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a phase II, dose-finding study Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 ACCLaim/COPD II: efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist in COPD patients, a phase III study Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study}, Source: Eur Respir J 2012; 40: 830-836 Year: 2012 Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009 The efficacy of long-acting anticholinergic agent, tiotropium bromide on dynamic hyperinflation in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006 Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012 A comparison of early bronchodilating responses of Salbutamol, Ipratropium bromide, and the combination of Ipratropium bromide-Salbutamol in stable patients with COPD or asthma Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002 Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008 Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006 Low systemic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Tiotropium bromide (TIO) reduces hospitalizations in patients with COPD who had been refractory to treatment with combined inhaled corticosteroid/long acting beta agonist (ICS/LABA) Source: Eur Respir J 2005; 26: Suppl. 49, 717s Year: 2005 The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD Source: Eur Respir J 2007; 30: Suppl. 51, 356s Year: 2007 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013